Adalimumab ameliorates abdominal aorta cross clamping which induced liver injury in rats

Biomed Res Int. 2014:2014:907915. doi: 10.1155/2014/907915. Epub 2014 Jan 16.

Abstract

The aim of this study was to investigate the possible protective effects of adalimumab (ADA) on cell damage in rat liver tissue during ischemia/reperfusion (I/R) injury of infrarenal abdominal aorta. Thirty male Wistar-albino rats were divided into three groups: control, I/R, and I/R+ADA, each group containing 10 animals. Laparotomy without I/R injury was performed in the control group animals. Laparotomy in the I/R group was followed by two hours of infrarenal abdominal aortic cross ligation and then two hours of reperfusion. ADA (50 mg/kg) was administered intraperitoneally as a single dose, to the I/R+ADA group, five days before I/R. The tumor necrosis factor-alpha (TNF-α) (pg/mg protein) and nitric oxide (NO) (µmol/g protein) levels in the I/R group (430.8 ± 70.1, 8.0 ± 1.1, resp.) were significantly higher than those in the I/R+ADA group (338.0 ± 71.6, P = 0.006; 6.3 ± 1.2, P = 0.008) and the control group (345.5 ± 53.3, P = 0.008; 6.5 ± 1.5, P = 0.010, resp.). I/R causes severe histopathological injury to the liver tissue, but ADA leads to much less histopathological changes. ADA treatment significantly decreased the severity of liver I/R injury. ADA pretreatment may have protective effects on experimental liver injury.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adalimumab
  • Animals
  • Antibodies, Monoclonal, Humanized / pharmacology*
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Aorta, Abdominal / injuries*
  • Immunohistochemistry
  • Liver / chemistry
  • Liver / drug effects*
  • Male
  • Nitric Oxide / analysis
  • Nitric Oxide / metabolism
  • Rats
  • Rats, Wistar
  • Reperfusion Injury / drug therapy
  • Reperfusion Injury / metabolism*
  • Statistics, Nonparametric
  • Tumor Necrosis Factor-alpha / analysis
  • Tumor Necrosis Factor-alpha / metabolism

Substances

  • Antibodies, Monoclonal, Humanized
  • Tumor Necrosis Factor-alpha
  • Nitric Oxide
  • Adalimumab